A citation-based method for searching scientific literature

Elena García-Martínez, Andres Redondo, Josep Maria Piulats, Analía Rodríguez, Antonio Casado. Angiogenesis 2020
Times Cited: 4







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar, Dan G Duda, Rakesh K Jain. Nat Rev Clin Oncol 2018
461
50

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Jonathan A Ledermann, Allan Hackshaw, Stan Kaye, Gordon Jayson, Hani Gabra, Iain McNeish, Helena Earl, Tim Perren, Martin Gore, Mojca Persic,[...]. J Clin Oncol 2011
153
25

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
H Hirte, S Lheureux, G F Fleming, A Sugimoto, R Morgan, J Biagi, L Wang, S McGill, S P Ivy, A M Oza. Gynecol Oncol 2015
37
25


Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
941
25

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Radoslav Chekerov, Felix Hilpert, Sven Mahner, Ahmed El-Balat, Philipp Harter, Nikolaus De Gregorio, Claudius Fridrich, Susanne Markmann, Jochem Potenberg, Ralf Lorenz,[...]. Lancet Oncol 2018
35
25

Recurrent ovarian cancer.
E Pujade-Lauraine, P Combe. Ann Oncol 2016
18
25

A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Mingming Miao, Guanming Deng, Sujuan Luo, Jiajia Zhou, Le Chen, Jun Yang, Jie He, Junjun Li, Jing Yao, Shanmei Tan,[...]. Gynecol Oncol 2018
41
25

Anti-angiogenic agents in ovarian cancer: past, present, and future.
B J Monk, L E Minion, R L Coleman. Ann Oncol 2016
72
25


Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Debra L Richardson, Michael W Sill, Robert L Coleman, Anil K Sood, Michael L Pearl, Siobhan M Kehoe, Michael E Carney, Parviz Hanjani, Linda Van Le, Xun C Zhou,[...]. JAMA Oncol 2018
31
25

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
165
25

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
850
25

Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.
Jindi Zhang, Anyang Li, Qi Jiang, Feiyun Zheng, Haiyan Zhu. Drug Des Devel Ther 2019
5
25

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M Del Campo, Petronella Ottevanger,[...]. Lancet Oncol 2016
126
25

Roles of the immune system in cancer: from tumor initiation to metastatic progression.
Hugo Gonzalez, Catharina Hagerling, Zena Werb. Genes Dev 2018
416
25

Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.
Jae-Weon Kim, Sven Mahner, Ling-Ying Wu, Tadahiro Shoji, Byoung-Gie Kim, Jian-Qing Zhu, Tadao Takano, Sang-Yoon Park, Bei-Hua Kong, Qiang Wu,[...]. Int J Gynecol Cancer 2018
17
25

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
25

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Daniela Sambataro, Stefano Tamberi, Saverio Cinieri, Anna M Mosconi, Michele Orditura, Alba A Brandes, Valentina Arcangeli,[...]. Lancet Oncol 2015
86
25

Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.
Binyan Lin, Xiuming Song, Dawei Yang, Dongsheng Bai, Yuyuan Yao, Na Lu. Gene 2018
106
25

Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.
Sebastien Gouy, Alexandra Arfi, Amandine Maulard, Patricia Pautier, Enrica Bentivegna, Alexandra Leary, Cyrus Chargari, Catherine Genestie, Philippe Morice. Oncologist 2019
11
25

Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Richard Wyn Griffiths, Ying-Kiat Zee, Saran Evans, Claire L Mitchell, Gireesh C Kumaran, Richard S Welch, Gordon C Jayson, Andrew R Clamp, Jurjees Hasan. Int J Gynecol Cancer 2011
40
25

Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Ai-Ping Zhou, Yuxian Bai, Yan Song, Hong Luo, Xiu-Bao Ren, Xiuwen Wang, Benkang Shi, Cheng Fu, Ying Cheng, Jiyan Liu,[...]. Oncologist 2019
23
25

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
25

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade.
Qian Yang, Laichao Ni, Saber Imani, Zhangqiang Xiang, Rui Hai, Ruilin Ding, Shaozhi Fu, Jing Bo Wu, Qinglian Wen. Cancer Manag Res 2020
6
25

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
C F Verschraegen, S Czok, C Y Muller, L Boyd, S J Lee, T Rutledge, S Blank, B Pothuri, S Eberhardt, F Muggia. Ann Oncol 2012
32
25

Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
25

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Stephen A Cannistra, Ursula A Matulonis, Richard T Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey Douglas, Robert A Burger, Deborah Armstrong, Robert Wenham,[...]. J Clin Oncol 2007
536
25

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
25

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
81
25


Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
Kathryn F McGonigle, Howard G Muntz, Jacqueline Vuky, Pamela J Paley, Dan S Veljovich, Benjamin E Greer, Barbara A Goff, Heidi J Gray, Thomas W Malpass. Cancer 2011
50
25

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.
Li Sun, Meng Yang, Xuan Zhang, Hua Li, Lingying Wu, Yuzi Zhang, Shangli Cai. Medicine (Baltimore) 2020
2
50

A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Shoji Nagao, Ai Kogiku, Kazuhiro Suzuki, Takashi Shibutani, Kasumi Yamamoto, Tomoatsu Jimi, Miho Kitai, Takaya Shiozaki, Kazuko Matsuoka, Satoshi Yamaguchi. J Ovarian Res 2020
4
25


Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Andres M Poveda, Frédéric Selle, Felix Hilpert, Alexander Reuss, Antonella Savarese, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Nana Scotto, Lada Mitchell,[...]. J Clin Oncol 2015
93
25

Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Chun-Yan Lan, Yin Wang, Ying Xiong, Jun-Dong Li, Jing-Xian Shen, Yan-Fang Li, Min Zheng, Yan-Na Zhang, Yan-Ling Feng, Qing Liu,[...]. Lancet Oncol 2018
67
25

Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.
J Niu, M N Kundranda, M Markman, J Farley. Eur J Gynaecol Oncol 2017
3
33

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
U A Matulonis, R T Penson, S M Domchek, B Kaufman, R Shapira-Frommer, M W Audeh, S Kaye, L R Molife, K A Gelmon, J D Robertson,[...]. Ann Oncol 2016
84
25

Anlotinib: First Global Approval.
Yahiya Y Syed. Drugs 2018
47
25

Angiogenesis in epithelian ovarian cancer.
E S Bamberger, C W Perrett. Mol Pathol 2002
109
25


Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
639
25

Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Yuhui Huang, Shom Goel, Dan G Duda, Dai Fukumura, Rakesh K Jain. Cancer Res 2013
329
25

Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs.
Pierre Fons, Geneviève Gueguen-Dorbes, Jean-Pascal Herault, Fabien Geronimi, Joël Tuyaret, Dol Frédérique, Paul Schaeffer, Cécile Volle-Challier, Jean-Marc Herbert, Françoise Bono. J Cell Physiol 2015
17
25


Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa.
Eric T Clambey, Eóin N McNamee, Joseph A Westrich, Louise E Glover, Eric L Campbell, Paul Jedlicka, Edwin F de Zoeten, John C Cambier, Kurt R Stenmark, Sean P Colgan,[...]. Proc Natl Acad Sci U S A 2012
316
25


The vascular network of tumours--what is it not for?
Efthimios Sivridis, Alexandra Giatromanolaki, Michael I Koukourakis. J Pathol 2003
47
25

Phenotypical and functional specialization of FOXP3+ regulatory T cells.
Daniel J Campbell, Meghan A Koch. Nat Rev Immunol 2011
549
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.